TLV •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization18.65 mln
Float1,851 mln
Earnings Date08/06/2026
EPS
4.63
Solid
P / E
0.00
Anomalous
Piotroski F-Score
2
/ 9
Weak
Relative Strength
62
/ 100
Outperforming
Debt / Equity
0.02
Debt-free
ROE
-111
Deeply negative
Business Description
Purple Biotech Ltd. is an Israel-based clinical-stage oncology company working to help cancer patients whose tumors resist standard treatments or evade the immune system. The company is advancing several experimental drugs, including two compounds currently in Phase 2 trials targeting pancreatic cancer, head and neck cancer, and colorectal cancer, as well as an early-stage antibody program aimed at stimulating the body's immune response against tumors. Purple Biotech is also partnering with Bristol Myers Squibb to test one of its lead therapies alongside a widely used immune checkpoint drug.
